LRMR has 957% upside potential with strong financial stability; analysts optimistic about company's future.

From Yahoo Finance: 2025-05-21 11:22:00

Larimar Therapeutics, Inc. (LRMR) is a biotech company with a 957% upside potential, focusing on developing treatments for rare genetic disorders like Friedreich’s ataxia (FA). Despite a recent share price decline due to adverse events related to its experimental therapy, LRMR maintains strong financial stability with $157.5 million in cash as of March 31, 2025.

LRMR’s proprietary intracellular delivery platform enables effective treatment of rare diseases with cellular deficiencies. Analysts are optimistic about the company’s potential, projecting a 957.52% upside with a twelve-month price target of $20.04. Larimar Therapeutics is at the forefront of developing transformative therapies for rare diseases, positioning itself as a leader in the biotech sector.



Read more at Yahoo Finance: Analysts See 957% Upside Potential